What is Qudexy XR?
Qudexy XR is a prescription medicine sold in the United States. It contains topiramate in an extended-release (XR) form, meaning the medicine is designed to release gradually over time.
It is used to treat migraine in adults and to help prevent migraine headaches (not to treat a migraine attack once it starts). Qudexy XR is also prescribed for certain seizure disorders as directed by a clinician. [1]
What is “XR” and how is Qudexy XR different from regular topiramate?
“XR” stands for extended-release. Compared with immediate-release topiramate, Qudexy XR is formulated so the drug stays in your body longer and typically has a different dosing schedule. This can affect how often people take it and how steady the medication level is. [1]
What conditions is it prescribed for?
Qudexy XR is indicated for:
- Prevention of migraine headaches in adults [1]
- Seizure control for certain seizure types, as specified on the product labeling [1]
How do people typically take Qudexy XR?
The medication is taken by mouth as a prescription and is usually taken once daily because of the extended-release design. Exact dosing depends on the specific condition, your starting dose, and how your body responds. [1]
What side effects do people ask about?
Common questions about topiramate medicines include side effects such as:
- Tingling in the hands or feet
- Sleepiness or fatigue
- Dizziness
- Nausea
- Changes in appetite or weight
- Trouble with concentration or memory
Serious risks also exist for topiramate products (for example, metabolic acidosis and eye-related emergencies). Patients should review the medication guide and contact a clinician if they develop concerning symptoms. [1]
Is Qudexy XR the same as other topiramate products?
Qudexy XR is a brand name for extended-release topiramate. Other products may be:
- Immediate-release topiramate, which is not the same as XR
- Other brand or generic formulations with different release profiles
Because dosing and side effects can vary by formulation, switching products should be done only under prescriber guidance. [1]
Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/